2016~2018年南京地区下丘脑和腺垂体激素类药物应用分析

Analysis of Clinical Application of Hypothalamic Pituitary Hormone Drugs in Hospitals of Nanjing During 2016 to 2018

目的:了解南京地区2016~2018年下丘脑和腺垂体激素类药物的临床应用情况,评估其变化趋势。方法:对2016~2018年南京地区44家医院使用的下丘脑和腺垂体激素类药物的品种、销售金额、构成比、用药频度(DDDs)、限定日费用等进行统计分析。结果:2016~2018年南京地区下丘脑和腺垂体激素类药物销售金额年增长率分别为28.82%和-0.18%。销售金额居前列的是奥曲肽、生长抑素、戈舍瑞林、亮丙瑞林、曲普瑞林和卵泡刺激素,占年总销售金额、DDDs值比例均超过70%;而戈那瑞林、加尼瑞克、促肾上腺能皮质激素的销售金额、DDDs连续3年排在末位,且占总销售金额、DDDs值比例不到0.2%。结论:下丘脑和腺垂体激素类药物在南京地区医院应用广泛,销售金额和使用量整体上呈增长后趋于平稳的趋势,大部分药物的限定日费用呈降低趋势。

Objective:To evaluate the application and tendency of hypothalamic pituitary hormone drugs in 44 hospitals in Nanjing during 2016 to 2018.Methods:To analyze the varieties,sales amount,composition ratio,medication frequency and daily drug cost of hypothalamic pituitary hormone drugs in 44 hospitals in Nanjing.Results:The annual increased rate of the sales amount of hypothalamic pituitary hormone drugs was 28.82%and-0.18%,respectively.The large amount of sales was octreotide,somatostatin,goserelin,leuprorelin,triptorelin and follicle stimulating hormone.The total annual sales amount and DDDs exceeded 70%.However,the consumption sum and DDDs of gonadorelin,ganirelix and adrenocorticotropine ranked last in 3 consecutive years,and the ratio was less than 0.2%.Conclusion:The hypothalamic pituitary hormone drugs are widely used in hospitals in Nanjing,the sales amount and usage as a whole showed a trend of stabilization after growth,and the vast majority of daily drug cost is decreasing.